LONDON: AstraZeneca started late-stage trials on Saturday of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months. The Phase III international clinical trial will recruit a total of 5,000 people across countries in Europe and the United States to assess the …
Read More »AstraZeneca starts new COVID-19 prevention trials of antibody cocktail
November 21, 2020